Cart is empty Despite recent advances, ovarian cancer remains the fifth leading cause of cancer-related deaths among women, and there’s a critical need for new treatment options, especially for advanced cancers that grow back after standard of care treatment. Results from a preclinical study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.
Leave A Comment